Trulieve Cannabis Corp. (NYSE:TRLV – Get Free Report) CEO Kim Rivers sold 139,846 shares of the business’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $9.46, for a total transaction of $1,322,943.16. Following the completion of the sale, the chief executive officer owned 2,898,539 shares in the company, valued at approximately $27,420,178.94. This trade represents a 4.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Trulieve Cannabis Stock Down 0.0%
Shares of NYSE:TRLV opened at $8.53 on Thursday. Trulieve Cannabis Corp. has a 12 month low of $3.42 and a 12 month high of $13.28.
Wall Street Analysts Forecast Growth
TRLV has been the subject of several analyst reports. Weiss Ratings began coverage on Trulieve Cannabis in a research note on Tuesday, June 16th. They issued a “sell (d-)” rating for the company. Zacks Research raised Trulieve Cannabis to a “hold” rating in a research report on Thursday, June 18th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Trulieve Cannabis presently has a consensus rating of “Reduce”.
Trulieve Cannabis Company Profile
Trulieve Cannabis Corp. is a vertically integrated cannabis company focused on the cultivation, processing, and retail sale of medical and adult-use cannabis products. The company offers a range of products that may include flower, pre-rolls, concentrates, edibles, vape products, and topicals through its dispensary network and branded product portfolio.
Trulieve’s operations have been centered primarily in the United States, with a strong presence in Florida and additional markets in other states where cannabis is legally regulated.
Featured Stories
- Five stocks we like better than Trulieve Cannabis
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Trulieve Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trulieve Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
